An Uncontrolled, Open-Label Extension Study to Evaluate the Long Term Safety, Tolerability, and Maintenance of Effect of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Raxatrigine (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors Biogen; Convergence Pharmaceuticals
- 01 Dec 2017 Planned End Date changed from 28 Feb 2019 to 22 Jul 2020.
- 01 Dec 2017 Planned primary completion date changed from 28 Feb 2019 to 22 Jul 2020.
- 28 Sep 2017 Planned End Date changed from 27 Dec 2018 to 28 Feb 2019.